Zacks Research Issues Negative Outlook for Masimo Earnings

Masimo Co. (NASDAQ:MASI - Free Report) - Analysts at Zacks Research lowered their Q3 2025 earnings per share (EPS) estimates for shares of Masimo in a research report issued to clients and investors on Tuesday, November 26th. Zacks Research analyst I. Bandyopadhyay now expects that the medical equipment provider will post earnings per share of $1.07 for the quarter, down from their previous forecast of $1.15. The consensus estimate for Masimo's current full-year earnings is $4.04 per share. Zacks Research also issued estimates for Masimo's Q1 2026 earnings at $1.09 EPS and Q2 2026 earnings at $1.17 EPS.

Several other research analysts also recently commented on the company. Wells Fargo & Company lifted their target price on Masimo from $160.00 to $171.00 and gave the stock an "overweight" rating in a report on Wednesday, November 6th. Needham & Company LLC reiterated a "hold" rating on shares of Masimo in a report on Wednesday, November 6th. BTIG Research boosted their price target on shares of Masimo from $166.00 to $170.00 and gave the company a "buy" rating in a research note on Monday, October 14th. Raymond James upgraded shares of Masimo from a "market perform" rating to an "outperform" rating and set a $170.00 price objective on the stock in a report on Wednesday, November 6th. Finally, Stifel Nicolaus reaffirmed a "buy" rating and set a $190.00 target price (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Masimo presently has an average rating of "Moderate Buy" and a consensus target price of $167.00.

Masimo Trading Down 0.8 %

NASDAQ:MASI traded down $1.37 during mid-day trading on Thursday, hitting $170.89. 534,498 shares of the company's stock were exchanged, compared to its average volume of 677,370. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. Masimo has a fifty-two week low of $91.60 and a fifty-two week high of $178.27. The company has a 50 day simple moving average of $147.03 and a 200-day simple moving average of $129.03. The firm has a market capitalization of $9.15 billion, a P/E ratio of 117.86 and a beta of 0.97.

Masimo (NASDAQ:MASI - Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, beating analysts' consensus estimates of $0.84 by $0.14. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm had revenue of $504.60 million for the quarter, compared to analyst estimates of $502.87 million. During the same period last year, the firm posted $0.63 earnings per share. The business's revenue for the quarter was up 5.4% on a year-over-year basis.

Institutional Investors Weigh In On Masimo

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MASI. Lazard Asset Management LLC raised its position in shares of Masimo by 5,730.0% in the first quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider's stock valued at $85,000 after purchasing an additional 573 shares during the period. Tidal Investments LLC lifted its position in shares of Masimo by 14.1% during the first quarter. Tidal Investments LLC now owns 2,179 shares of the medical equipment provider's stock worth $320,000 after acquiring an additional 269 shares in the last quarter. Farallon Capital Management LLC boosted its holdings in shares of Masimo by 13.6% in the first quarter. Farallon Capital Management LLC now owns 1,489,563 shares of the medical equipment provider's stock worth $218,742,000 after acquiring an additional 177,914 shares during the period. GAMMA Investing LLC grew its position in shares of Masimo by 75.0% in the second quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider's stock valued at $33,000 after purchasing an additional 111 shares in the last quarter. Finally, Juncture Wealth Strategies LLC lifted its holdings in Masimo by 294.3% during the 2nd quarter. Juncture Wealth Strategies LLC now owns 7,992 shares of the medical equipment provider's stock worth $1,007,000 after purchasing an additional 5,965 shares in the last quarter. 85.96% of the stock is currently owned by institutional investors.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.